Korro Bio Announces Submission to Start Phase 1/2 KRRO-121 Trial

What Happened

• On August 19, 2026, Korro Bio, Inc. announced it submitted an application to the Alfred Health Human Ethics Committee in Australia to initiate a first-in-human Phase 1/2 clinical trial of KRRO-121.
• KRRO-121 is a GalNAc‑conjugated RNA editing oligonucleotide being developed to treat hyperammonemia in patients with Urea Cycle Disorders (UCDs). The trial’s purpose is to assess safety and tolerability of escalating doses, evaluate pharmacokinetics, and measure effects in healthy volunteers and participants with UCDs. (ClinicalTrials.gov identifier: NCT07773246.)

Key Details

• Filing date: August 19, 2026 (Form 8-K).
• Ethics committee: Alfred Health Human Ethics Committee (Australia).
• Study: First-in-human Phase 1/2 to evaluate safety, tolerability, PK, and preliminary effect in healthy volunteers and UCD patients.
• Regulatory/risks note: Korro included standard forward-looking statement language and referenced risk disclosures in its Form 10-Q filed August 6, 2026.

Why It Matters

• This submission represents a key development milestone: moving KRRO-121 from preclinical to first-in-human testing, which is a critical step in clinical development and potential value creation for the program.
• For investors, trial initiation (and any subsequent approvals to enroll and dose patients) will materially affect clinical progress and future newsflow; however, the company warns that this is an early-stage program with the usual clinical, regulatory and enrollment risks.